FHDH-ANRS CO4 Cohort: HCV Incidence in MSM With HIV Declined Following Access to HCV DAA Therapy in France

March 8-11, 2020; Boston, Massachusetts
HCV incidence in MSM with HIV in France declined from 2014 to 2017 following unrestricted access of HCV DAA therapy for persons with HIV.
Format: Microsoft PowerPoint (.ppt)
File Size: 156 KB
Released: March 17, 2020

Acknowledgements

Provided by USF Health, in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Safety and efficacy of 24-wk oral regimens for pulmonary rifampicin-resistant TB in persons with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 4, 2022

Week 48 results from ALLIANCE study of BIC/FTC/TAF vs DTG plus FTC/TDF for HIV/HBV coinfection, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 3, 2022

Expert preview of data from the AIDS 2022 conference, including HIV cure, coinfections, long-acting PrEP, global progress toward UNAIDS 95-95-95 targets, and equity in healthcare access, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: July 13, 2022

person default Ariel Campos, MD person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Luis E. Soto-Ramirez, MD Released: June 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings